MedTrace Logo

Vactosertib and Durvalumab in Gastric Cancer

NCT04893252 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2022-11-30

No results posted yet for this study

Summary

This trial will test the efficacy and safety of durvalumab in combination with vactosertib in patients with metastatic gastric cancers who failed ≥ 2 lines of chemotherapy

Conditions

  • Stomach Neoplasm

Interventions

DRUG

durvalumab and vactosertib

durvalumab IV Q4W in combination with vactosertib PO bid (5 days a week)

Sponsors & Collaborators

  • Hark Kyun Kim

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04893252 on ClinicalTrials.gov